skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Auranofin (Code C65242)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Auranofin

Definition: An orally available, lipophilic, organogold compound, used to treat rheumatoid arthritis, with anti-inflammatory and potential antineoplastic activities. Auranofin interacts with selenocysteine residue within the redox-active domain of mitochondrial thioredoxin reductase (TrxR), thereby blocking the activity of TrxR. As a result, this agent induces mitochondrial oxidative stress leading to the induction of apoptosis. Furthermore, this agent strongly inhibits the JAK1/STAT3 signal transduction pathway, thereby suppressing expression of immune factors involved in inflammation. TrxR, overexpressed in many cancer cell types, inhibits apoptosis, promotes cell growth and survival and plays a role in resistance to chemotherapy; TrxR catalyzes the reduction of oxidized thioredoxin (Trx) and plays a central role in regulating cellular redox homeostasis.

Display Name: Auranofin

Label: Auranofin

NCI Thesaurus Code: C65242 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0699923  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)

External Source Codes: 
CAS Registry Number 34031-32-8 (see NLM ChemIDplus info)
FDA UNII Code 3H04W2810V
ChEBI ID CHEBI:2922 (see ChEBI info)
PDQ Closed Trial Search ID 710355
PDQ Open Trial Search ID 710355 (check for NCI PDQ open clinical trial info)
UMLS CUI C0699923

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C20H34AuO9PS
code C65242
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Auranofin
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom